Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

MicroRNA-based Drugs for Brain Tumours

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      School of Pharmacy Nottingham, U.K.; University of Nottingham, UK (UON)-University Park Nottingham, U.K.; Design and Application of Innovative Local Treatments in Glioblastoma (CRCINA-ÉQUIPE 17); Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA); Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE); Université de Nantes (UN)-Université de Nantes (UN); Centre de biophysique moléculaire (CBM); Université d'Orléans (UO)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS); GIN Grenoble Institut des Neurosciences (GIN); Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes 2016-2019 (UGA 2016-2019 ); This work was supported by Inca (Institut National du Cancer) through the PL-BIO 2014-2020 INCA project MARENGO - “MicroRNA agonist and antagonist Nanomedicines for GliOblastoma treatment: from molecular programmation to preclinical validation”. It is also related to the LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology” as part of the french government “Investissements d’Avenir” program. The authors are also thankful to the European support in the frame of the NanoFar consortium, an Erasmus Mundus Joint Doctorate (EMJD) program in nanomedicine and pharmaceutical innovation. European Commission (NanoFar EMJD), “Le Conseil Général de Maine-et-Loire” and Inca financially supported SA, AG and CL, respectively.
    • بيانات النشر:
      HAL CCSD
      Cell Press
    • الموضوع:
      2018
    • Collection:
      Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe)
    • نبذة مختصرة :
      Shubaash ANTHIYA and Audrey GRIVEAU contributed equally to this work. ; International audience ; MicroRNAs (miRNAs) are key regulatory elements coded by the genome. A single miRNA can downregulate expression of multiple genes involved in diverse functions. As cancer is a disease with multiple gene aberrations, developing novel approaches to identify and modulate miRNA-pathways may result in a breakthrough for cancer treatment. With a special focus on glioblastoma, this review provides an up-to-date understanding of miRNA biogenesis, role of miRNA in cancer resistance, essential tools for modulating miRNA expression, emerging list of clinically promising RNAi delivery systems and how they can be adapted for therapy.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/29506672; inserm-01691531; https://inserm.hal.science/inserm-01691531; https://inserm.hal.science/inserm-01691531v2/document; https://inserm.hal.science/inserm-01691531v2/file/GLIAD%28Anthiya%292018Eq17.pdf; PUBMED: 29506672
    • الرقم المعرف:
      10.1016/j.trecan.2017.12.008
    • Rights:
      info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.B54F374D